Vardenafil, a potent, highly selective phosphodiesterase-5 inhibitor for treating erectile dysfunction, does not impair
the ability of men with coronary artery disease (CAD) to exercise at levels equal to or greater than those reached during sexual intercourse, researchers report.
In a randomized crossover trial, Dr. Udho Thadani from Oklahoma University, Oklahoma City, and colleagues studied 41 men with stable exertional angina due to CAD and erectile dysfunction. The men were randomly assigned in crossover fashion to vardenafil 10 mg or placebo and after 1 hour they underwent exercise tolerance testing at 5-10 metabolic equivalents (METS).
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!